Background: Medical therapies for hidradenitis suppurativa (HS) are often ineffective. Tumor necrosis factor-a inhibitors may be a potential treatment for patients with moderate to severe HS.
H idradenitis suppurativa (HS) is a common inflammatory disease characterized by painful, recurrent abscesses and nodules primarily in intertriginous areas.
1,2 HS has a point prevalence of 1% to 4% in the general population, is more common in women than men, and has an average age of onset in the mid 20s to early 30s.
formation, scarring, discharge, pain, the development of squamous cell carcinoma, and serious impairments in health-related quality of life. 6 Current treatments are often unsatisfactory. Medical therapies, such as systemic antibiotics, provide only temporary relief of symptoms. Surgical interventions can be curative but are associated substantial morbidity and a high risk of recurrence of hidradenitis.
Tumor necrosis factor (TNF)-a is a proinflammatory cytokine that has numerous effects at the cellular level, and these effects may be relevant to the inflammatory aspects of HS. [7] [8] [9] Initially, patients with Crohn disease with concomitant HS showed improvement of their HS lesions when treated with the anti-TNF-a agent infliximab. [10] [11] [12] Subsequently, more than 70 patients were reported in the literature who were treated with a TNF-a inhibitor (infliximab, etanercept, adalimumab). [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Most of these patients showed some clinical response while receiving treatment, with some patients demonstrating significant periods of remission. However, most of these studies were case reports or case series and few were derived from prospectively conducted clinical trials.
Etanercept is a TNF-a inhibitor that is Food and Drug Administration approved for the treatment of multiple inflammatory conditions including rheumatoid arthritis, psoriatic arthritis, and psoriasis. To better estimate the safety and potential efficacy of etanercept for treatment of HS, we performed an open-label prospective clinical trial in patients with severe hidradenitis who had not responded adequately to existing standard treatment regimens.
METHODS

Study patients
Institutional review board approval was obtained and all patients gave informed consent to participate. The study was conducted in accordance with the Declaration of Helsinki and was registered at ClinicalTrials.gov (NCT00107991) before any study procedures were performed. Patients were eligible if they were age 18 years or older. Participants were required to have severe HS clinically confirmed by the investigator and defined as Hurley stage II or III disease, and have 4 or more lesions (eg, nodules or abscesses) that had not responded to previous standard therapies such as topical or oral antibiotics, isotretinoin, or intralesional steroid injections. 23 Patients were required to use at least one form of effective contraception during the study period if female and of childbearing capacity. All male patients were required to use at least one form of effective contraception during the study period. Female patients who elected to use a hormonal form of contraception must have initiated the hormonal contraception at least 90 days before the start of the study drug and continued using this in the same form until the end of the study (week 18), or they were excluded from the study. Patients were excluded if they had used oral or topical antibiotics, isotretinoin, or intralesional steroids within 30 days before or at any time during the study period. Patients who used systemic immunosuppressants, an investigational medication, or a live vaccine 90 days before day 0 of this study were excluded. Patients were excluded if they experienced an active moderate to severe infection or an infection requiring treatment with antibiotics within 30 days of day 0 of the study, had a history of tuberculosis or positive screening visit purified protein derivative, or had a known history of an immune-suppressive disease. Patients who had clinically significant laboratory abnormalities, had severe comorbidities, had history of alcohol or drug abuse within 12 months of the screening visit, were pregnant or lactating, or were using concurrent cyclophosphamide were also excluded.
Study design
This was a prospective, single-arm, single-dose, noncontrolled, open-label, modified Simon twostage clinical trial of 50 mg of etanercept/wk administered subcutaneously (SC) in patients with stage II or III HS. 24 The study took place at a university department of dermatology. During an 18-week trial, etanercept (50 mg) was administered SC once a week for 12 weeks. At week 12, etanercept was tapered to 25 mg/wk during a 2-week period to minimize the risk of a flare of their disease. The patients were then followed up for an additional 4 weeks after discontinuing the study drug on week 14. Patients returned to clinic at baseline and weeks 2, 4, 8, 12, 14, and 18. The first participant was enrolled on May 26, 2005 , and all visits were completed by August 7, 2008 .
Efficacy end points
The primary efficacy measure was the proportion of patients classified as responders using the Physician Global Assessment (PGA) on a 100-mm visual analog scale, with 0 mm corresponding to no active disease (only residual scars remain) and 100 mm corresponding to very severe disease with multiple, painful, inflammatory lesions. Visual analog scales to assess global response in clinical trials of hidradenitis have been previously accepted. 25 A patient was classified as a responder if the individual achieved at least a 50% reduction on the PGA score at week 12 compared with baseline. A single dermatologist (R. L.), who was blinded to the definition of a responder and the starting and stopping rules of the study, graded all study patients except one (patient 11 was graded by dermatologist J. T.).
Secondary outcome measures included number of lesions (nodules and abscesses) and patientreported outcomes including a patient global assessment rating, a patient self-report of pain on a 100-mm visual analog scale (with 0 corresponding to no pain and 100 mm corresponding to severe pain), and the Dermatology Life Quality Index (DLQI). All measures were compared from baseline to week 12, with responders defined as those achieving at least a 50% reduction in number of lesions, a 50% reduction in the pain score, a 50% improvement in the DLQI score, or a moderate or greater improvement in the patient global assessment.
Safety end points
All patients who received at least one dose of study drug were included in the safety analysis. Patients were carefully assessed at each visit for evidence of adverse events, including serious adverse events, malignancies, infections, and adverse events suggestive of hypersensitivity. A complete blood cell count, chemistry panel, and renal and liver function tests were performed at baseline and at week 12.
Statistical analysis
The study was conducted using a modified Simon two-stage design to maximize the safety and efficiency of this early phase II clinical trial. We assumed that 50% of patients would be classified as responders on the PGA at week 12 as defined above. We determined that if 20% or fewer patients were classified as responders, then this agent would not be promising for future studies at the current dose. In addition, we assumed a type I error of 0.05 and a type II error of 0.1. Thus, if the true responder rate is less than 20%, then the probability of this study recommending further investigation is 5%, and if the true response rate is 50% or more, then the probability of recommending the current dose of etanercept for further study is 90%. In the first stage of the study, 12 patients were enrolled and their response status was determined at week 12. With the above assumptions, if 3 or more of the first 12 patients who received study drug were classified as responders at week 12, then this would justify treating an additional 9 patients in stage 2. The primary analysis included all participants who were enrolled in the trial and received any treatment (intention to treat [ITT ]) with response rates reported using two methods. In the ITT analysis, all patients who did not reach week 12 were classified as nonresponders. As a sensitivity analysis, we also performed an ITT analysis using the last outcome carried forward for all efficacy measures. The first 12 patients who entered the trial and received study drug were used to determine whether an additional 9 patients would be enrolled based on the a priori rule described above. Additional patients were enrolled to allow for an as treated (AT) analysis of up to 12 patients. The AT analysis included all patients who completed treatment with etanercept up to week 12 of the study, which provided the basis for an effectiveness analysis.
For the primary outcome, responders were classified based on PGA scores at week 12 compared with baseline, and response rates were calculated with 95% confidence intervals. In addition, response rates with 95% confidence intervals were calculated for all secondary outcome measures. The median and interquartile range values were calculated at baseline and at week 12 for the PGA, the number of hidradenitis lesions, the DLQI, and the patient report of pain. Comparisons were made using the Wilcoxon signed rank test. Data analysis was performed using software (STATA, Version 10, StataCorp LP, College Station, TX).
RESULTS
A total of 38 patients were assessed for eligibility (Fig 1) and 15 patients were enrolled. Of these, 10 patients completed the 12-week treatment period and 5 patients withdrew during the treatment period. Of the 10 patients who completed the treatment period, 8 completed the posttreatment assessment at Table I and are further divided into an ITT population and an AT population. The ITT and AT populations were similar in terms of sex, age, race, duration of disease, prior therapies, body mass index (BMI), and baseline assessments and there were no significant differences in patients who completed 12 weeks of treatment compared with those who did not (data not shown). The physician-observed outcomes are shown in Table II and Fig 2, A. The ITT population median baseline PGA score was 4.35 and lesion count was 14 and these scores decreased slightly after 12 weeks of treatment to 3.5 (P = .14) and 12 (P = .69), respectively. Only two of the first 12 patients were classified as responders based on our a priori definition (indicating a lack of efficacy) and, therefore, we did not enroll a complete second stage based on our a priori starting and stopping rule. The AT analysis yielded similar results for the physician-observed outcomes (Table II and Fig 2, A) . Of note, the 3 patients who did achieve a clinical response had a lower median BMI (27.5) than those who did not achieve a clinical response (36); however, this was not statistically significant (P = .31).
The patient-reported outcome measures are shown in Table III and Fig 2, A and B . In the ITT analysis the median pain score diminished from 6.4 to 4.1 (P = .08) and the DLQI scores improved slightly from a median of 19 to 15 (P = .02). Although DLQI scores improved statistically, the improvement was of minimal clinical significance based on the magnitude of the change. 26 Although 57% of patients reported some improvement, no one reported complete remission at 12 weeks and only 29% of patients reported a moderate improvement in their disease.
The results of the AT analysis were similar to the ITT analysis for patient-reported outcomes. The time course of both physician-and patient-reported outcomes was similar in demonstrating some improvement by week 4. Both outcome measures seemed to show a maximum improvement by week 8 and a worsening once the treatment was stopped at week 14 (Fig 2) .
The incidence of adverse events is shown in Table  IV . In general, etanercept was well tolerated and there were no serious adverse events reported. A total of 38 adverse events were reported in 14 patients. Both ITT and AT populations had similar adverse event profiles with upper respiratory infections reported between 26% and 30% of the time. Other adverse events were uncommon and included nausea, paresthesias, skin infection, arthralgias, and elevation of cholesterol levels. Of the patients who failed to complete the treatment period, two stopped because of skin infections at the site of HS lesions requiring oral antibiotics, one stopped because of worsening paresthesias as a result of carpal tunnel syndrome, and two stopped because of logistical issues (transportation issues or incarceration).
DISCUSSION
HS is a devastating inflammatory disease for which no medical therapies are proven to be consistently efficacious. The unmet medical need for safe and efficacious treatments for HS is illustrated by the long distances patients traveled to enter this study (median distance [ 150 miles), and the severe impairment in health-related quality of life at baseline as measured by the DLQI. 26 The results of our study demonstrate that etanercept (50 mg/wk SC) is well tolerated in patients with HS, but has minimal evidence of clinically significant efficacy. Particular strengths of this study include its prospective nature, the systematic collection of safety and efficacy data, use of both physician-and patient-reported outcomes, and assessments by a physician who was blinded to the design of the trial and definitions of clinical response.
There have been at least two other prospective studies of etanercept for the treatment of hidradenitis. Giamarellos-Bourboulis et al 27 conducted an open-label phase II trial of etanercept (50 mg/wk) for 12 weeks in 10 patients. The primary outcome measure was a disease activity score that demonstrated that 6 of 10 patients had greater than 50% improvement. Similar findings were seen when using the Sartorius scale. When using a patientreported visual analog scale to assess improvement, only 2 of 10 patients had greater than 50% improvement at week 12, suggesting that the improvements may not have been clinically significant. Cusack and Buckley 28 reported an open-label study of 6 patients using etanercept (50-100 mg) every week. All of the patients improved, with 4 of 5 evaluable patients showing greater than 50% improvement in DLQI score. In this study, 4 of 6 patients experienced disease flares requiring use of oral antibiotics during treatment with etanercept and, therefore, some of the observed efficacy may have been a result of concomitant antibiotic use.
At least two prospective studies have been performed using infliximab for HS. Mekkes and Bos 29 studied the long-term benefit of infliximab by giving a standard week 0, 2, and 6 dosing schedule and evaluating the long-term efficacy using the Sartorius score. The average score diminished from 164 6 50 (mean 6 SD) before treatment to 89 6 49 after 1 year (P = .002). DLQI scores showed a 50% or greater improvement at 1 year in 5 of 10 patients. Fardet et al 17 reported 7 patients prospectively treated with infliximab induction treatment of 5 mg/kg at weeks 0, 2, and 6 and were evaluated at weeks 6 and 10. The Sartorius score demonstrated improvement of greater than 50% in 2 of 7 patients. The same two patients reported marked improvement in both the physicianand patient-reported improvement scales and more than 50% improvement on the Skindex-29 scale in at least one category (symptom, emotion, or function). Several patients experienced significant adverse reactions and the authors concluded that the efficacy of infliximab in patients with severe HS seems transient and is associated with significant side effects.
The existing prospective studies of TNF-a inhibitors for hidradenitis have varied in their outcome assessment, population studied, and dose and type of TNF-a inhibitor used. In particular, these studies tended to find higher responses when using the Sartorius score compared with using global assessment tools. Our study did not use the Sartorius score; however, our results clearly demonstrate a lack of significant clinical response based on the results of our patient-and physician-reported outcomes. Further studies are needed to determine the best y For all outcome variables under intention-to-treat (ITT ) analysis, median values were calculated with last outcome carried forward for patients who withdrew from study.
z Under both ITT and as-treated (AT) analyses, blinded physician outcome measures were missing for 3 patients at week 2 and for two patients at week 14. In these instances, median values were calculated without those particular patients. outcome measurement for hidradenitis studies. In addition, it is possible that differences in patient population could have affected the outcomes of the study. In particular, in psoriasis, it has been suggested that etanercept efficacy may be diminished in patients with an elevated BMI. 26, 30 The median BMI of our study population was 35 and, therefore, it is possible that etanercept may be more effective in patients with HS who have an ideal BMI. In fact, in our study, responders had a lower BMI than nonresponders; however, this finding was not statistically significant. Finally, none of these studies used a control group and, therefore, it is possible that observed benefits could be as a result of natural remissions, a placebo effect, or, in some studies, the allowance of concomitant therapies that can improve HS.
In conclusion, our study demonstrated minimal evidence of clinically significant efficacy of etanercept (50 mg/wk SC) in the treatment of hidradenitis. Future studies using higher doses of etanercept are indicated; however, patients need to be carefully monitored for infection and other adverse events. Ultimately, randomized, controlled trials will be necessary to demonstrate the risk-to-benefit ratio of TNF-a inhibitors in the treatment of hidradenitis. 
